Primary central nervous system T-cell lymphoma: An analysis from the surveillance, epidemiology, and end results program

Long, Hao; Li, Siyi; Zhang, Yuzhen; Li, Ruqi; Fong, Tszhei; Yang, Chen; Wang, Hai; Xu, Nan; Xu, Yingjie; Wang, Kewan; Yang, Kailin; Qi, Songtao; Wang, Jun

doi:10.1016/j.jocn.2020.07.020

Cited by 4 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…148 Estimates of average age at diagnosis range from 55.8 to 60 years. 149,150 Interestingly, a recent systematic review described a much lower median age at diagnosis for those with primary CNS anaplastic large cell lymphoma (PCNS-ALCL), at 21 years (range 1-82 years). 151 Mature peripheral TCLs comprise a spectrum of biologically and clinically heterogeneous malignancies.…”

Section: Burkitt Lymphomamentioning

confidence: 99%

“…A large case series comprising a range of histopathological subtypes estimated patients with PCNS-TCL have a short median OS of 8 months with a 3-year OS of 32.8%. 150 Specifically for patients with PCNS-ALCL, a systematic review of reported cases found that ALK-positive tumours were associated with superior 2-year OS rates compared to ALK-negative neoplasms (71% vs. 22%). 151 However, this observation may be confounded by age; the ALK-positive group was significantly younger than the ALK-negative cohort (17.5 vs. 63 years).…”

Section: Burkitt Lymphomamentioning

confidence: 99%

“…Primary CNS T‐cell lymphomas (PCNS‐TCL) account for between 2% and 8.5% of all primary lymphomas within the CNS, 145–147 with a reported higher incidence in Eastern countries 148 . Estimates of average age at diagnosis range from 55.8 to 60 years 149,150 . Interestingly, a recent systematic review described a much lower median age at diagnosis for those with primary CNS anaplastic large cell lymphoma (PCNS‐ALCL), at 21 years (range 1–82 years) 151 …”

Section: Subtypes Of Rare Cns Lymphomamentioning

confidence: 99%

See 2 more Smart Citations

Rare central nervous system lymphomas

2022

View full text Add to dashboard Cite

Central nervous system (CNS) lymphomas are rare malignancies characterised by lymphoid infiltration into the brain, spinal cord, cranial nerves, meninges and/or eyes in the presence or absence of previous or concurrent systemic disease. Most CNS lymphomas are of the diffuse large B‐cell lymphoma (DLBCL) subtype for which treatment strategies, particularly the use of high‐dose methotrexate‐based protocols and consolidation with autologous stem cell transplantation, are well established. Other histopathological subtypes of CNS lymphoma are comparatively less common with published data on these rare lymphomas dominated by smaller case series and retrospective reports. Consequently, there exists little clinical consensus on the optimal methods to diagnose and manage these clinically and biologically heterogeneous CNS lymphomas. In this review article, we focus on rarer CNS lymphomas, summarising the available clinical data on incidence, context, diagnostic features, reported management strategies, and clinical outcomes.

show abstract

Section: Burkitt Lymphomamentioning

confidence: 99%

Section: Burkitt Lymphomamentioning

confidence: 99%

Section: Subtypes Of Rare Cns Lymphomamentioning

confidence: 99%

See 1 more Smart Citation

Rare central nervous system lymphomas

2022

View full text Add to dashboard Cite

show abstract

“…Primary central nervous system lymphoma (PCNSL) is a rare lymphoma that accounts for 2–6% of all primary brain tumors. [ 1 , 3 , 4 , 9 , 11 , 14 , 23 , 24 , 31 , 33 - 35 ] Only 2% of these cases are known to be of T-cell origin. [ 1 , 2 , 4 , 6 , 11 , 13 , 15 , 17 , 21 - 23 , 25 - 29 , 31 - 35 ] T-cell PCNSL has less than a 20–30% 5-year survival rate.…”

Section: Introductionmentioning

confidence: 99%

“…[ 1 , 3 , 4 , 9 , 11 , 14 , 23 , 24 , 31 , 33 - 35 ] Only 2% of these cases are known to be of T-cell origin. [ 1 , 2 , 4 , 6 , 11 , 13 , 15 , 17 , 21 - 23 , 25 - 29 , 31 - 35 ] T-cell PCNSL has less than a 20–30% 5-year survival rate. [ 14 , 35 ] Therefore, early and accurate diagnosis and treatment is imperative for best clinical outcomes.…”

Section: Introductionmentioning

confidence: 99%

Primary peripheral T-cell central nervous system lymphoma

Bird

Traylor

Thomas

et al. 2021

Surgical Neurology International

View full text Add to dashboard Cite

Background: Primary peripheral T-cell central nervous system lymphoma (PCNSL) is a rare, aggressive tumor that arises in the craniospinal axis and has an increased risk in individuals who are immunocompromised. This lesion often mimics other benign and malignant processes on radiographic imaging, leading to misdiagnosis and delays in treatment. We present a case of a patient with a history of Sjögren’s syndrome and progressive neurologic symptoms who underwent craniotomy for diagnosis. Case Description: A 61-year-old woman with a history of Sjögren’s syndrome, progressive aphasia, left facial droop, and right-sided paresthesias for 4 months presented for evaluation and management. An enhancing, infiltrative lesion in the left frontal lobe with underlying vasogenic edema was appreciated and suggestive of a primary or metastatic neoplasm. The patient underwent an open biopsy for further evaluation of the lesion. Extensive histopathologic evaluation revealed a diagnosis of T-cell PCNSL. The patient was started on induction methotrexate and temozolomide followed by consolidative radiotherapy. Conclusion: Autoimmune conditions are a risk factor for T-cell PCNSL development. T-cell PCNSL has radiographic and gross histologic features that are consistent with a broad differential, including gliomas and inflammatory processes. Prompt diagnosis and extensive histopathological evaluation is essential to ensure appropriate treatment.

show abstract

The epidemiology and prognosis of patients with primary gastric T‐cell lymphoma in the SEER program

et al. 2022

View full text Add to dashboard Cite

Background Primary gastric T‐cell lymphoma (PG‐TCL) is a rare hematological malignancy with few data reported. The objective of this study is to investigate the epidemiology, clinical characteristics, and survivals of PG‐TCL. Methods Totally, 164 patients with PG‐TCL from 1975 to 2016 extracted from the Surveillance, Epidemiology, and End Results Program (SEER) database were analyzed. Kaplan–Meier method was applied to plot overall survival (OS) and cancer‐specific survival (CSS). The prognostic factors of OS and CSS were explored by Cox proportional hazard regression. Nomograms were constructed to predict survival possibilities. Results The age‐adjusted incidence rate of PG‐TCL was 0.0091 per 100,000 person‐years and increased with age. The median age at onset was 65 years old with male predominance. The major histological type was peripheral T‐cell lymphoma, NOS (63.4%). The 1‐, 2‐, and 5‐year OS were 45.5%, 34.7%, and 23.5%, respectively while the 1‐, 2‐, and 5‐year CSS were 47.4%, 37.3%, and 29.6%, respectively. Multivariate Cox analysis demonstrated that age at diagnosis, use of chemotherapy, and radiotherapy were the independent prognostic factors for OS. Chemotherapy combined with radiotherapy could significantly improve patients' OS compared with chemotherapy alone. Moreover, age at diagnosis and use of chemotherapy were also the independent prognostic factors for CSS. Nomograms for PG‐TCL were developed to predict 1‐, 2‐, and 5‐year OS possibilities. The predictability of nomograms was verified by high concordance index and good agreement with the predicted value in calibration plots. Conclusion PG‐TCL is a rare neoplasm with low incidence. Patients with PG‐TCL generally exhibited poor prognosis. Use of chemotherapy plus radiotherapy was associated with favorable OS.

show abstract

Primary central nervous system T-cell lymphoma: An analysis from the surveillance, epidemiology, and end results program

Cited by 4 publications

References 31 publications

Rare central nervous system lymphomas

Rare central nervous system lymphomas

Primary peripheral T-cell central nervous system lymphoma

The epidemiology and prognosis of patients with primary gastric T‐cell lymphoma in the SEER program

Contact Info

Product

Resources

About